-
- Kensuke Kojima
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Steven M. Kornblau
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Vivian Ruvolo
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Archana Dilip
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Seshagiri Duvvuri
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- R. Eric Davis
- Department of Lymphoma and Myeloma,
-
- Min Zhang
- Department of Lymphoma and Myeloma,
-
- Zhiqiang Wang
- Department of Lymphoma and Myeloma,
-
- Kevin R. Coombes
- Department of Bioinformatics and Computational Biology, and
-
- Nianxiang Zhang
- Department of Bioinformatics and Computational Biology, and
-
- Yi Hua Qiu
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Jared K. Burks
- Section of Molecular Hematology and Therapy, Department of Leukemia,
-
- Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and
-
- Sharon Shacham
- Karyopharm Therapeutics, Boston, MA
-
- Michael Kauffman
- Karyopharm Therapeutics, Boston, MA
-
- Michael Andreeff
- Section of Molecular Hematology and Therapy, Department of Leukemia,
書誌事項
- 公開日
- 2013-05-16
- DOI
-
- 10.1182/blood-2012-08-447581
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>High CRM1 expression was associated with short survival of AML patients. CRM1 inhibitor KPT-185 induces apoptosis mainly in a p53-dependent manner, whereas inhibition of proliferation was p53 independent.</jats:p>
収録刊行物
-
- Blood
-
Blood 121 (20), 4166-4174, 2013-05-16
American Society of Hematology
